Pharmacogenomics can be defined in a broad sense as investigating the relationship between genomics and how single or different individuals vary in response to medication. This includes efficacy, dose adjustment, adverse reactions, and identifying novel medicinal targets. Research in pharmacogenomics has grown considerably in recent decades thanks to rapid advances in technology. However, it has had limited success in discovering genes that correspond to drug efficacy in most therapeutic areas, with the exception of oncology where somatic mutations in tumour tissues are often associated with treatment efficacy. As a result, much research in pharmacogenomics has been dedicated to adverse drug reactions (ADRs) but this has yet to be properly implemented in clinical practice. Pharmacogenomics of ADRs has tremendous potential to improve health outcomes since ADRs can lead to drug withdrawal leading to a cessation or delay in treatment. In addition, ADRs are estimated to be the 4th leading cause of death in the United States, causing more deaths than pulmonary disease, diabetes, AIDS, pneumonia and accidents. However, the exact number of ADRs is uncertain due to limitations in methodological considerations.
One lesson that has been learnt from the COVID19 pandemic is that under particular circumstances health care systems can fall short of resources. ADRs are a huge burden for health care systems worldwide, and a growing concern, due to the increase in the prevalence of multiple morbidities and the related use of medications. A considerable proportion of ADRs could be preventable with the implementation of precision medicine and the use of pharmacogenomics. The aim of this Research Topic is to provide a collection of papers that will ideally facilitate the implementation of pharmacogenomics to prevent ADRs. We welcome Original Research, Case Reports, and Review articles covering the following topics:
- Novel genetic associations with ADRs. Manuscripts that replicate/meta-analyse previous associations implementing robust methodologies are also welcome. Please note that we will take in consideration only association studies with a strong functional basis and with enough statistical power.
- Challenges (scientific, economic, or regulatory) in implementing pharmacogenomics to identify ADRs in clinical practice.
- The cost-effectiveness of using genomic tests to identify ADRs before prescribing a medication.
- Pharmacogenomics of ADRs in diverse populations or ethnicities, particularly the less studied ones.
- The molecular basis of ADRs that are reported to be associated with a genomic marker.
- Patients/clinicians attitude and knowledge about the pharmacogenomics of ADRs.
Topic Editor Hamid Mahmoudpour is employed by Merk KGaA. The other Topic Editors have no conflict of interest with the Research Topic theme
Pharmacogenomics can be defined in a broad sense as investigating the relationship between genomics and how single or different individuals vary in response to medication. This includes efficacy, dose adjustment, adverse reactions, and identifying novel medicinal targets. Research in pharmacogenomics has grown considerably in recent decades thanks to rapid advances in technology. However, it has had limited success in discovering genes that correspond to drug efficacy in most therapeutic areas, with the exception of oncology where somatic mutations in tumour tissues are often associated with treatment efficacy. As a result, much research in pharmacogenomics has been dedicated to adverse drug reactions (ADRs) but this has yet to be properly implemented in clinical practice. Pharmacogenomics of ADRs has tremendous potential to improve health outcomes since ADRs can lead to drug withdrawal leading to a cessation or delay in treatment. In addition, ADRs are estimated to be the 4th leading cause of death in the United States, causing more deaths than pulmonary disease, diabetes, AIDS, pneumonia and accidents. However, the exact number of ADRs is uncertain due to limitations in methodological considerations.
One lesson that has been learnt from the COVID19 pandemic is that under particular circumstances health care systems can fall short of resources. ADRs are a huge burden for health care systems worldwide, and a growing concern, due to the increase in the prevalence of multiple morbidities and the related use of medications. A considerable proportion of ADRs could be preventable with the implementation of precision medicine and the use of pharmacogenomics. The aim of this Research Topic is to provide a collection of papers that will ideally facilitate the implementation of pharmacogenomics to prevent ADRs. We welcome Original Research, Case Reports, and Review articles covering the following topics:
- Novel genetic associations with ADRs. Manuscripts that replicate/meta-analyse previous associations implementing robust methodologies are also welcome. Please note that we will take in consideration only association studies with a strong functional basis and with enough statistical power.
- Challenges (scientific, economic, or regulatory) in implementing pharmacogenomics to identify ADRs in clinical practice.
- The cost-effectiveness of using genomic tests to identify ADRs before prescribing a medication.
- Pharmacogenomics of ADRs in diverse populations or ethnicities, particularly the less studied ones.
- The molecular basis of ADRs that are reported to be associated with a genomic marker.
- Patients/clinicians attitude and knowledge about the pharmacogenomics of ADRs.
Topic Editor Hamid Mahmoudpour is employed by Merk KGaA. The other Topic Editors have no conflict of interest with the Research Topic theme
